GE and Thermo Fisher Scientific have entered into an agreement under which GE Healthcare will acquire Thermo Fisher’s HyClone cell culture media and sera, and gene modulation and magnetic beads businesses, for approximately $1.1 billion. The acquisition expands GE’s R&D technologies in cell biology and cell therapy for the discovery and manufacture of new drugs, vaccines and diagnostics. The acquired businesses had combined annual revenues of approximately $250 million in 2013. The acquisiti...